annb0t
Top 20
MELBOURNE, Australia, July 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)Â today announces that it has dosed the final patient and completed recruitment into the Phase III pivotal study ZIRCON (Zirconium in Renal Cancer Oncology, NCT03849118) of its investigational renal (kidney) cancer imaging agent TLX250-CDx (89Zr-DFO-girentuximab). This global study has dosed 300 patients to date, exceeding the target enrolment of 252 patients, announced on 8 March 20...
>>> Read more: ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
>>> Read more: ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
